NEURALAGENT
3.6.2024 10:01:27 CEST | Business Wire | Press release
Airbus Defence and Space, a leader in the aerospace industry, and NeuralAgent, an innovative AI start-up, have signed two contracts that will help shape the Future Combat Air System (FCAS) programme. This tri-national programme led by the Ministries of Defence from France, Germany and Spain marks a significant step forward in strengthening European Defence Systems, notably through cutting-edge artificial intelligence. This partnership between Airbus and NeuralAgent will contribute to the FCAS’ Combat Cloud, as part of the global phase 1B contract.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530772952/en/
Figure 1: Signing Ceremony, People from left to right, Jennifer Klaschka- Marketing and Operations at NeuralAgent, Dr. -Ing Onur Deniz CEO at NeuralAgent, Dirk Sprünken Procurement at Airbus, Juan Emilio Murillo Martinez, Head of Procurement Software and Cyber Security at Airbus, Luis Mager – Procurement at Airbus (Photo: Business Wire)
The partnership focuses on bridging the innovation gap with an AI-defined, non-jammable, resilient, and self-organizing network and system architectures in the air, on the ground or in space. The aim is to automate and optimize the response times of an unlimited number of combat nodes, reducing them to real time or milliseconds. This initiative will leverage Airbus Defence and Space's advanced infrastructure and NeuralAgent’s cutting-edge decentralized AI technology to deliver redundant, explainable, and high-performant collaborative Agents under dynamic environments. This aims to outperform costly central AI-Approaches with a single point of failure against jamming. Together, they seek to transform defense capabilities with unprecedented and distributed autonomous intelligence of large number of combat nodes.
Dr. -Ing Onur Deniz, CEO of NeuralAgent, emphasized the importance of this collaboration: "This contract is a pivotal achievement for NeuralAgent as it allows us to not only redefine the future of AI-defined Secure and Resilient Networks through our foundational AI-Agent Models but also extends our reach into dual-use cases for commercial industries from space to ground, supporting scalable innovation across the EU."
Juan Emilio Murillo Martinez, Head of Procurement Software and Cyber Security at Airbus Defence and Space, highlighted the benefits of this partnership: "Working with disruptive AI start-ups such as NeuralAgent, will propel our innovation efforts and help us stay ahead with the latest AI trends. This collaboration will enhance our capabilities in both legacy and future systems, ensuring we remain at the forefront of technological advancements."
This strategic partnership between Airbus Defence and Space and NeuralAgent aims to transform European defense AI capabilities, showcasing their commitment to innovation and leadership in the EU's biggest defense project.
About Airbus Defence and Space
Airbus Defence and Space is a division of Airbus Group responsible for defence and aerospace products and services. The company is a leader in designing, developing, and manufacturing military aircraft, space systems, and connected intelligence systems and services.
About NeuralAgent
NeuralAgent is an AI start-up specializing in the development of Decentralized AI-Agent Foundation Models for distributed autonomous intelligence and shaping the future of Telecoms, Mobility, NewSpace, Robotics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530772952/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom